CoChat
Sign Up
Cited by 131PARP inhibition in cancer therapyBRCA gene mutations in cancerOvarian cancer diagnosis and treatment

The DOI matches its Crossref record.

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Drew, Y., de Jonge, M., Hong, S.H., Park, Y.H., Wolfer, A., Brown, J., Ferguson, M., Gore, M.E., Alvarez, R.H., Gresty, C., Angell, H., Meyer, K., Learoyd, M., Tang, M., Lanasa, M., Herbolsheimer, P., Domchek, S.M.·2018·Gynecologic Oncology
DOI 10.1016/j.ygyno.2018.04.555
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ygyno.2018.04.555

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

Sorted by citations

Items 101–131 of 131

Related

See all

Metadata

Authors
Drew, Y., de Jonge, M., Hong, S. H., Park, Y. H., Wolfer, A., Brown, J., Ferguson, M., Gore, M. E., Alvarez, R. H., Gresty, C., Angell, H., Meyer, K., Learoyd, M., Tang, M., Lanasa, M., Herbolsheimer, P., & Domchek, S. M.
Affiliations
  • Newcastle University (GB)
  • The Catholic University of Korea Seoul St. Mary's Hospital (KR)
  • Samsung Medical Center (KR)
  • Centre Hospitalier Universitaire Vaudois (CH)
  • Beatson West of Scotland Cancer Centre (GB)
  • NHS Tayside (GB)
  • Royal Marsden Hospital (GB)
  • AstraZeneca (United Kingdom) (GB)
  • AstraZeneca (United States) (US)
  • University of Pennsylvania (US)
Corresponding author
Drew, Y.
ORCID
Venue
Gynecologic Oncology
Publisher
Elsevier BV
Published
2018-06
Volume
149
Pages
246-247
ISSN
0090-8258 (ISSN-L)
DOI
10.1016/j.ygyno.2018.04.555
OpenAlex
W2811158315
Cited by
131
References
0
Citations by year
2026: 2 · 2025: 7 · 2024: 4 · 2023: 14 · 2022: 12 · 2021: 19 · 2020: 37 · 2019: 30 · 2018: 6
FWCI
8.70
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
Gynecologic Oncology (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords
olaparib, durvalumab, germline BRCA mutation, platinum-sensitive recurrent ovarian cancer, PARP inhibitors, PD-L1 inhibitors, combination therapy, maintenance therapy, treatment efficacy and safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review